natgillin/translations-raw huggingface dataset:
The pharmaceutical dosage formulation of claim 5, wherein the binder and adhesive are selected from the group consisting of acacia gum; guar gum; tragacanth gum; sucrose; gelatin; glucose; starch; cellulosics such as methylcellulose, sodium carboxymethylcellulose, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose; and water soluble or dispersible binders such as alginic acid and salts thereof, magnesium aluminum silicate, hydroxyethylcellulose, polyethylene glycol, polysaccharide acids, bentonites, polyvinylpyrrolidone, polymethacrylates, and pregelatinized starch. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što su vezivo i adheziv izabrani iz grupe koju čine akacija guma; guar guma; tragakant guma; saharoza; želatin; glukoza; škrob; celuloze kao što su metilceluloza, natrij karboksimetilceluloza, etilceluloza, hidroksipropilmetilceluloza, hidroksipropilceluloza; i u vodi topljiva ili disperzibilna veziva kao što je alginska kiselina i njene soli, magnezij aluminij silikat, hidroksietilceluloza, polietilen glikol, polisaharidne kiseline, bentoniti, polivinilpirolidon, polimetakrilati, i preželatinizirani škrob.
The pharmaceutical dosage formulation of claim 5, wherein the disintegrant is selected from the group consisting of starches such as corn starch and potato starch; sodium starch glycolates; pregelatinized starches such as corn starch; clays such as magnesium aluminum silicate; celluloses such as crosslinked sodium carboxymethylcellulose and microcrystalline cellulose; alginates; gums such as agar, guar, locust bean, karaya, pectin, and tragacanth gum; and cross-linked polyvinylpyrrolidone. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što je dezintegrator izabran iz grupe koju čine škrobovi kao što su kukuruzni škrob i krumpirov škrob; natrij škrobni glikolat; preželatinizirani škrobovi kao što je kukuruzni škrob; gline kao što je magnezij aluminij silikat; celuloze kao što je umrežena natrij karboksimetilceluloza i mikrokristalna celuloza; alginati; gume poput agar, guar, rogač, karaja, pektin, i tragakant gume; i umreženi polivinilpirolidon.
The pharmaceutical dosage formulation of claim 5, wherein the lubricant and antiadherent is selected from the group consisting of stearates such as magnesium stearate, calcium stearate and sodium stearate; stearic acid; talc waxes; stearowet; boric acid; sodium chloride; DL-leucine; carbowax 4000; carbowax 6000; sodium oleate; sodium benzoate; sodium acetate; sodium lauryl sulfate; and magnesium lauryl sulfate. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što su lubrikant i antiadheziv izabrani iz grupe koju čine stearati kao što su magnezij stearat, kalcij stearat i natrij stearat; stearinska kiselina; talk voskovi; stearovet; borna kiselina; natrij klorid; DL-leucin; carbovax 4000; carbovax 6000; natrij oleat; natrij benzoat; natrij acetat; natrij lauril sulfat; i magnezij lauril sulfat.
The pharmaceutical dosage formulation of claim 5, wherein the glidant is selected from the group consisting of talc, cornstarch, and silica. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što je glidant izabran iz grupe koju čine talk, kukuruzni škrob i silika.
The pharmaceutical dosage formulation of any of claims 1-11 for use in a method of treating or ameliorating a δ or µ opioid receptor mediated disorder selected from pain and gastrointestinal disorders, wherein the method comprises administering the pharmaceutical dosage formulation to a subject in need of such treatment. 
Farmaceutska dozna formulacija prema bilo kojem od patentnih zahtjeva od 1 do 11 za upotrebu u postupku za liječenje ili ublažavanje poremećaja posredovanog δ ili µ opioidnim receptorima, koji je izabran između bola i gastrointestinalnih poremećaja, pri čemu se postupak sastoji od davanja farmaceutskog preparata subjektu kojem je takav tretman potreban.
The pharmaceutical dosage formulation for use as claimed in claim 12, wherein the pharmaceutical dosage formulation is administered at a frequency of one to four administrations per day. 
Farmaceutska dozna formulacija za upotrebu prema patentnom zahtjevu 12, naznačena time što se farmaceutska formulacija administrira sa frekvencijom od jedne do četiri administracije dnevno.
The pharmaceutical dosage formulation for use as claimed in claim 12, wherein the pharmaceutical dosage formulation is administered once daily. 
Farmaceutska dozna formulacija za upotrebu prema patentnom zahtjevu 12, naznačena time što se farmaceutska dozna formulacija administrira jedanput dnevno.
The pharmaceutically acceptable salt of claim 19, wherein the salt is a hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic, or trifluoroacetic acid salt. 
Farmaceutski prihvatljiva sol prema patentnom zahtjevu 19, naznačena time, što sol predstavlja sol klorovodične, bromovodične, jodovodične, perklorne, sumporne, dušične, fosforne, octene, propionske, glikolne, mliječne, jantarne, maleinske, fumarne, jabučne, vinske, limunske, benzojeve, bademove, metansulfonske, hidroksietansulfonske, benzensulfonske, oksalne, 2-naftalensulfonske, p-toluensulfonske, cikloheksansulfaminske, salicilne, saharinske ili soli trifluoroctene kiseline.
Identity document (1) according to claim 1 or 2, wherein the ghost image (D) comprises at least two images of the person on the identity card (1) of which at least one of the two images is a calculated image. 
Identifikacijski dokument (1) prema zahtjevu 1 ili 2, gdje fantomska slika (D) sadrži najmanje dvije slike osobe na identifikacijskoj kartici (1) od kojih je najmanje jedna od dvije slike proračunata slika.
Identity document (1) according to claim 3, wherein the at least one of the two images is a rotated image over an angle in the range from about 4,5 ° to about 7,5 °, preferably over an angle of about 6 °. 
Identifikacijski dokument (1) prema zahtjevu 3, gdje je najmanje jedna od dvije slike rotirana slika duž kuta u opsegu od približno 4,5° do približno 7,5°, a prvenstveno duž kuta od približno 6°.
Identity document (1) according to claim 3 or 4, wherein the at least one of the two images is a rotated image over an angle in the range from about -4,5 ° to about -7,5 °, preferably over an angle of about -6 °. 
Identifikacijski dokument (1) prema zahtjevu 3 ili 4, gdje je najmanje jedna od dvije slike rotirana slika duž kuta u opsegu od oko -4,5° do približno oko -7,5°, prvenstveno duž kuta od oko -6°.
Identity document (1) according to any of the preceding claims, wherein the ghost image (D) consists of more than two images. 
Identifikacijski dokument (1) prema bilo kojem od prethodnih zahtjeva, gdje se fantomska slika (D) sastoji od više od dvije slike.
Identity document (1) according to claim 7, wherein the lenses (8, 9, 10) of the lens array (7) are spherical shaped. 
Identifikacijski dokument (1) prema zahtjevu 7, gdje su leće (8, 9, 10) niza (7) leće oblikovane sferno.
Identity document (1) according to any of the preceding claims, wherein the images are being applied offset relative to one another and overlapping one another in an image layer (11). 
Identifikacijski dokument (1) prema bilo kojem od prethodnih zahtjeva, gdje se slike nanose pomaknuto jedna u odnosu na drugu tako da preklapaju jedna drugu na sloju (11) za sliku.
Identity document (1) according to any of the preceding claims, wherein the images are overlapped with respect to each other in such a way that the angle of observation of different images is about 6 ° to 15 °. 
Identifikacijski dokument (1) prema bilo kojem od prethodnih zahtjeva, gdje su slike preklopljene jedna u odnosu na drugu na takav način da je kut promatranja različitih slika oko od 6° do 15°.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-((6-(trans-4-tert-butylcyclohexyloxy)quinazolin-2-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(trans-4-tert-butilcikloheksiloksi)kinazolin-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-(1-(6-(trans-4-tert-butylcyclohexyloxy)naphthalen-2-yl)-2,2,2-trifluoroethyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-(1-(6-(trans-4-tert-butilcikloheksiloksi)naftalen-2-il)-2,2,2-trifluoroetil) piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-((6-(cis-4-ethylcyclohexyloxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(cis-4-etilcikloheksiloksi)naftalen-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-((2-(trans-4-tert-butylcyclohexyloxy)quinolin-6-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((2-(trans-4-tert-butilcikloheksiloksi)kinolin-6-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-(6-(trans-4-tert-butylcyclohexyloxy)-2-naphthoyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-(6-(trans-4-tert-butilcikloheksiloksi)-2-naftoil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-((6-((4-tert-butylcyclohexylidene)methyl)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-((4-tert-butilcikloheksiliden)metil)naftalen-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-3-methyl-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-3-metil-piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-4-phenyl-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-4-fenil-piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-perhydro-azepine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-perhidro-azepin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-[7-(trans-4-tert-butyl-cyclohexyloxy)-isoquinolin-3-ylmethyl]-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[7-(trans-4-tert-butil-cikloheksiloksi)-izokinolin-3-ilmetil]-piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-((6-(cyclopentyloxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(ciklopentiloksi)naftalen-2-il)metil)piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-((6-(tetrahydro-2H-pyran-4-yloxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(tetrahidro-2H-piran-4-iloksi)naftalen-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound or pharmaceutically acceptable salt for use according to claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-piperidine-2-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-piperidin-2-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
A package as claimed in Claim 1, wherein the fold line (19) is discontinuous and formed by cutting through the material of the sealing flap (5). 
Pakiranje u skladu sa patentnim zahtjevom 1, naznačeno time što je linija (19) savijanja napravljena isjecanjem ili uklanjanjem materijala iz brtvenog kapka (5).
The material according to anyone of claims 1-7 wherein the outer protective layer (A) and the inner protective layer (B) or the inner protective layer (B) and the substrate compound layer (C) are bond with an adhesive. 
Materijal temeljem bilo kojeg zahtjeva od 1 do 7 naznačen time da su vanjski zaštitni sloj (A) i unutarnji zaštitni sloj (B) ili unutarnji zaštitni sloj (B) i sloj spojeva supstrata (C) spojeni ljepilom.
The use of a material according to anyone of claims 1-11 for protection purpose. 
Uporaba materijala temeljem bilo kojeg zahtjeva od 1 do 11 naznačena time što je u zaštitne svrhe.
The use of a material according to anyone of claims 1-11 for thermal and/or acoustic insulation and/or acoustic and/or vibration damping insulation and/or fire protection insulation. 
Uporaba materijala temeljem bilo kojeg zahtjeva od 1 do 11 naznačena time što je za toplinsku i/ili zvučnu izolaciju i/ili zvučnu i/ili vibracijsku amortizaciju i/ili izolaciju od vatre.
The use of a material according to claim 16 for thermal and/or sound insulation and/or fire protection insulation inside and outside of structures, vessels, containers and pipes, such as walls, ceilings, floors, roofs, tanks, tubes, and ducts. 
Uporaba materijala temeljem zahtjeva 16 naznačena time što je za toplinsku i/ili zvučnu izolaciju i/ili izolaciju od vatre unutar i izvan građevina, plovila, kontejnera i cijevi, kao što su zidovi, stropovi, podovi, krovovi, cisterne, cijevi i kanali.
High purity degree safinamide or ralfinamide or a salt thereof with a pharmaceutically acceptable acid for the treatment according to any one of claims 4 and 5 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight). 
Safinamid ili ralfinamid visoke čistoće, ili njihove soli s farmaceutski prihvatljivom kiselinom, namijenjeni liječenju u skladu s patentnim zahtjevom 1, naznačen time što je farmaceutski prihvatljiva kiselina metansulfonska kiselina, a sadržaj odgovarajućih nečistoća formule (IIa) ili (IIb) u obliku soli s metansulfonskom kiselinom je niži od 0,01% (težinski).
A pharmaceutical formulation containing high purity degree safinamide or ralfinamide or a salt thereof with a pharmaceutically acceptable acid according to claim 1. 
Farmaceutska formulacija, naznačena time što sadrži safinamid ili ralfinamid visoke čistoće, ili njihove soli s farmaceutski prihvatljivom kiselinom, u skladu s patentnim zahtjevom 1.
A pharmaceutical formulation according to claim 3 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight). 
Farmaceutska formulacija u skladu s patentnim zahtjevom 3, naznačen time što je farmaceutski prihvatljiva kiselina metansulfonska kiselina, a sadržaj odgovarajućih nečistoća formule (IIa) ili (IIb) u obliku soli s metansulfonskom kiselinom je niži od 0,01% (težinski).
A pharmaceutical formulation according to claim 3 which contains one or more additional active agent(s) in addition to high purity degree safinamide or ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the respective impurity of formula (IIa) or (IIb) or a salt thereof with a pharmaceutically acceptable acid is lower than 0.03% (by weight). 
Farmaceutska formulacija u skladu s patentnim zahtjevom 3, naznačena time što sadrži jedno ili više dodatnih aktivnih sredstava uz safinamid ili ralfinamid visoke čistoće, ili njihove soli s farmaceutski prihvatljivom kiselinom, gdje je sadržaj odgovarajućih nečistoća formule (IIa) ili (IIb), ili njihovih soli s farmaceutski prihvatljivom kiselinom, niži od 0,03% (težinski).
A pharmaceutical formulation according to claim 5 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight). 
Farmaceutska formulacija u skladu s patentnim zahtjevom 5, naznačena time što je farmaceutski prihvatljiva kiselina metansulfonska kiselina, a sadržaj odgovarajućih nečistoća formule (IIa) ili (IIb) u obliku soli s metansulfonskom kiselinom je niži od 0,01% (težinski).
wherein said secondary part (P2) comprises an electromagnetic unit (UEM) and wherein the secondary part output set (TOUT1, TOUT2) comprises at least: 
pri čemu navedeni sekundarni dio (P2) obuhvaća elektromagnetsku jedinicu (UEM) i gdje izlazni red sekundarnog dijela (TOUT1, TOUT2) obuhvaća najmanje sljedeće:
a third intermediate terminal (TINT3) connected to the output terminal of the first assembly (A1); 
treći srednji priključak (TINT3) spojen na izlazni priključak od prvog sklopa (A1);
a third output terminal (TOUT3), deriving from the third intermediate terminal (TINT3), arranged to provide a third output voltage (VOUT3) to be used for high frequency communications. 
treći izlazni priključak (TOUT3) koji proizlazi iz trećeg srednjeg priključka (TINT3), raspoređen u svrhu postavljanja trećeg izlaznog napona (VOUT3) koji se treba koristiti za visokofrekvencijske komunikacije.
wherein said unsubstituted or substituted 5-6 membered heterocyclyl ring formed by R20 and R21 and said unsubstituted or substituted 5-6 membered heterocyclyl ring of R23 are each independently unsubstituted or substituted with a C1-2 alkyl, a pharmaceutically acceptable carrier or excipient and at least one additional therapeutic agent. 
pri čemu su navedeni nesupstituirani ili supstituirani heterociklični prsten sa 5-6 članova formiran od R20 i R21 i navedeni nesupstituirani ili supstituirani heterociklični prsten sa 5-6 članova formiran od R23, nezavisno nesupstituirani ili supstituirani sa C1-2 alkilom, farmaceutski prihvatljiv nosač ili ekscipijens i najmanje jedan dodatni terapijski agens.
High purity degree safinamide or ralfinamide or a salt thereof with a pharmaceutically acceptable acid for the treatment according to claim 1, wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight). 
Safinamid ili ralfinamid visoke čistoće, ili njihove soli s farmaceutski prihvatljivom kiselinom, namijenjeni liječenju u skladu s patentnim zahtjevom 1, naznačen time što je farmaceutski prihvatljiva kiselina metansulfonska kiselina, a sadržaj odgovarajućih nečistoća formule (IIa) ili (IIb) u obliku soli s metansulfonskom kiselinom je niži od 0,01% (težinski).
The composition for use according to claim 1, wherein the composition is administered at a single dose volume of less than 5 mL or less than 3 mL. 
Sastav za upotrebu prema patentnom zahtjevu 1, pri čemu je sastav administriran u pojedinačnoj dozi čija je zapremnina manja od 5 ml ili manja od 3 ml.
The composition for use according to claim 1 or 2, wherein the intrathecal administration of the composition does not result in substantial adverse effect in the subject. 
Sastav za upotrebu prema patentnom zahtjevu 1 ili 2, pri čemu intratekalna administracija sastava ne rezultira značajnim neželjenim efektima kod subjekta.
The composition for use according to any one of claims 1 to 3, wherein the administration interval is once every two weeks, once every month or once every two months. 
Sastav za upotrebu prema bilo kojem od patentnih zahtjeva od 1 do 3, pri čemu je interval administracije jednom svaka dva tjedna, jednom mjesečno ili jednom u dva mjeseca.
The composition for use according to any one of the preceding claims, wherein the lysosomal storage disease is selected from the group consisting of Hunters Syndrome, metachromatic leukodystrophy (MLD) disease, Sanfilippo syndrome type A, and globoid cell leukodystrophy (GLD) disease. 
Sastav za upotrebu prema bilo kojem od prethodnih zahtjeva, gdje je lizozomska bolest nakupljanja izabrana iz grupe koju sadrže Hunterov sindrom, bolest metakromatske leukodistrofije (MLD), Sanfilipp-ov sindrom tipa A i bolest leukodistrofije globoidnih stanica (GLD).
The composition for use according to any one of claims 1-4, wherein the replacement enzyme is optionally selected from the group consisting of recombinant iduronate-2-sulfatase (I2S), arylsulfatase A (ASA), heparan N-sulfatase (HNS). 
Sastav za upotrebu prema bilo kojem od patentnih zahtjeva od 1 do 4, gdje je enzim izmjene opcionalno izabran iz grupe koju čine rekombinantna idunorat-2-sulfataza (I2S), arilsulfataza A (ASA), heparan N-sulfataza (HNS).
The composition for use according to any one of the preceding claims, wherein the composition achieves a therapeutic concentration of the lysosomal enzyme within the affected cells and tissues of the CNS, in particular the brain. 
Sastav za upotrebu prema bilo kojem od prethodnih zahtjeva, pri čemu postiže terapeutsku koncentraciju lizozomskog enzima unutar zahvaćenih stanica i tkiva CNS-a, posebno mozga.
An inhibitor of IL-6 activity which is an antibody or functionally-active fragment, which antibody or functionally-active fragment binds to IL-6 or to the IL-6R and interferes with IL-6R-ligand interaction or binds to IL-6 and interferes with the IL-6-gp130 interaction, for use in the treatment and/or prophylaxis of glomerulonephritis associated with a vasculitic disorder. 
Inhibitor IL-6 aktivnosti koji je antitijelo ili funkcionalno aktivni fragment, koje antitijelo ili funkcionalno aktivni fragment se vezuje za IL-6 ili za IL-6R i utječe na IL-6R-ligand interakciju ili se vezuje za IL-6 i utječe na IL-6-gp130 interakciju, za upotrebu u liječenju i/ili profilaksi glomerulonefritisa povezanog sa vaskulitis poremećajem.
A Biological Control Agent (BCA) system comprising processed parasitized mealybug mummies; wherein said processed parasitized mealybug mummies are essentially devoid of their limbs and waxy covering. 
Sustav sredstva za biološku kontrolu (BCA) koji obuhvaća obrađene mumije parazitiranih vunastih ušiju; naznačen time da su navedene obrađene mumije parazitiranih vunastih ušiju u osnovi lišene udova i voštanog pokrova.